All In Biotech

Drug Trial Radar · NCT06242691

Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

13

Actual

Start

Feb 28, 2024

Primary completion

Jun 17, 2025

Study completion Jun 17, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses

Conditions

  • Advanced Solid Tumors

Interventions

  • MK-1200Biological

    IV Infusion

  • AntiemeticDrug

    One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1Time frame: During the first two 14-day cycles (Up to approximately 28 days)
  2. Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2Time frame: Up to approximately 12 months
  3. Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2Time frame: Up to approximately 9 months

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004)

    Louisville, Kentucky

  • START Midwest ( Site 0014)

    Grand Rapids, Michigan

  • South Texas Accelerated Research Therapeutics (START) ( Site 0005)

    San Antonio, Texas

  • START Mountain Region ( Site 0015)

    West Valley City, Utah

  • University of Virginia Health System-Hematology-Oncology ( Site 0009)

    Charlottesville, Virginia

  • The Alfred Hospital ( Site 0103)

    Melbourne, Victoria, Australia

  • Bradfordhill-Clinical Area ( Site 0301)

    Santiago, Region M. de Santiago, Chile

  • Beijing Cancer hospital-Digestive Oncology ( Site 0401)

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital-oncology department ( Site 0409)

    Fuzhou, Fujian, China

  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0415)

    Huai'an, Jiangsu, China

  • Rambam Health Care Campus-Oncology Division ( Site 0602)

    Haifa, Israel

  • Hadassah Medical Center ( Site 0604)

    Jerusalem, Israel

  • Rabin Medical Center-Oncology ( Site 0603)

    Petah Tikva, Israel

  • Sheba Medical Center ( Site 0605)

    Ramat Gan, Israel

  • Sourasky Medical Center ( Site 0601)

    Tel Aviv, Israel

  • Samsung Medical Center-Division of Hematology/Oncology ( Site 1003)

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.